MedTrace Logo

A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors

NCT05017623 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-11-18

No results posted yet for this study

Summary

This is an open-label, dose-escalation study of the study drug YH003 . The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of YH003 in subjects with advanced solid tumors.

Conditions

Interventions

DRUG

YH003

All subject will receive YH003 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.

Sponsors & Collaborators

  • Eucure (Beijing) Biopharma Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-26
Primary Completion
2023-03-02
Completion
2023-03-02

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05017623 on ClinicalTrials.gov